MedTrace Logo

MANP in Hypertension and Metabolic Syndrome

NCT03781739 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-11-13

No results posted yet for this study

Summary

Evaluate the cardiovascular and metabolic properties of MANP in subjects with HTN and MS according to rs5068 genotypes

Conditions

Interventions

DRUG

MANP

single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters

Sponsors & Collaborators

Principal Investigators

  • Paul M McKie, M.D. · Mayo Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-18
Primary Completion
2019-11-14
Completion
2019-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03781739 on ClinicalTrials.gov